-
1
-
-
0032893263
-
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
-
Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
-
(1999)
Cancer Res
, vol.59
, pp. 99-106
-
-
Fong, T.A.1
Shawver, L.K.2
Sun, L.3
Tang, C.4
App, H.5
Powell, T.J.6
-
2
-
-
0035866771
-
Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy
-
Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61: 2413-2419.
-
(2001)
Cancer Res
, vol.61
, pp. 2413-2419
-
-
Geng, L.1
Donnelly, E.2
McMahon, G.3
Lin, P.C.4
Sierra-Rivera, E.5
Oshinka, H.6
-
3
-
-
0036242810
-
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice
-
Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X et al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002; 16: 681-690.
-
(2002)
FASEB J
, vol.16
, pp. 681-690
-
-
Laird, A.D.1
Christensen, J.G.2
Li, G.3
Carver, J.4
Smith, K.5
Xin, X.6
-
4
-
-
0041672482
-
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models
-
Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63: 4009-4016.
-
(2003)
Cancer Res
, vol.63
, pp. 4009-4016
-
-
Schueneman, A.J.1
Himmelfarb, E.2
Geng, L.3
Tan, J.4
Donnelly, E.5
Mendel, D.6
-
5
-
-
0037102369
-
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
-
Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655.
-
(2002)
Cancer Res
, vol.62
, pp. 4645-4655
-
-
Wedge, S.R.1
Ogilvie, D.J.2
Dukes, M.3
Kendrew, J.4
Chester, R.5
Jackson, J.A.6
-
6
-
-
0034655182
-
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
-
Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
-
(2000)
Cancer Res
, vol.60
, pp. 2178-2189
-
-
Wood, J.M.1
Bold, G.2
Buchdunger, E.3
Cozens, R.4
Ferrari, S.5
Frei, J.6
-
7
-
-
33749238553
-
Discovery and development of sorafenib: A multikinase inhibitor for treating cancer
-
Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 835-844
-
-
Wilhelm, S.1
Carter, C.2
Lynch, M.3
Lowinger, T.4
Dumas, J.5
Smith, R.A.6
-
8
-
-
10744222964
-
Pharmacological characterization of CP-547 632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy
-
Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM et al. Pharmacological characterization of CP-547 632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003; 63: 7301-7309.
-
(2003)
Cancer Res
, vol.63
, pp. 7301-7309
-
-
Beebe, J.S.1
Jani, J.P.2
Knauth, E.3
Goodwin, P.4
Higdon, C.5
Rossi, A.M.6
-
9
-
-
3042548695
-
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts
-
Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
-
(2004)
Am J Pathol
, vol.165
, pp. 35-52
-
-
Inai, T.1
Mancuso, M.2
Hashizume, H.3
Baffert, F.4
Haskell, A.5
Baluk, P.6
-
10
-
-
20144370978
-
AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
-
Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-4400.
-
(2005)
Cancer Res
, vol.65
, pp. 4389-4400
-
-
Wedge, S.R.1
Kendrew, J.2
Hennequin, L.F.3
Valentine, P.J.4
Barry, S.T.5
Brave, S.R.6
-
11
-
-
3142774878
-
AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity
-
Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64: 4931-4941.
-
(2004)
Cancer Res
, vol.64
, pp. 4931-4941
-
-
Traxler, P.1
Allegrini, P.R.2
Brandt, R.3
Brueggen, J.4
Cozens, R.5
Fabbro, D.6
-
12
-
-
20044375603
-
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
-
Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7: 335-345.
-
(2004)
Angiogenesis
, vol.7
, pp. 335-345
-
-
Wang, Y.1
Fei, D.2
Vanderlaan, M.3
Song, A.4
-
13
-
-
0037386937
-
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma
-
Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003; 9: 1323-1332.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1323-1332
-
-
Posey, J.A.1
Ng, T.C.2
Yang, B.3
Khazaeli, M.B.4
Carpenter, M.D.5
Fox, F.6
-
14
-
-
0037076297
-
Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors
-
Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci U S A 2002; 99: 7009-7014.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 7009-7014
-
-
Niederman, T.M.1
Ghogawala, Z.2
Carter, B.S.3
Tompkins, H.S.4
Russell, M.M.5
Mulligan, R.C.6
-
15
-
-
1942452836
-
Progress in the clinical development of new marine-derived anticancer compounds
-
Jimeno J, Lopez-Martin JA, Ruiz-Casado A, Izquierdo MA, Scheuer PJ, Rinehart K. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 2004; 15: 321-329.
-
(2004)
Anticancer Drugs
, vol.15
, pp. 321-329
-
-
Jimeno, J.1
Lopez-Martin, J.A.2
Ruiz-Casado, A.3
Izquierdo, M.A.4
Scheuer, P.J.5
Rinehart, K.6
-
16
-
-
85047695382
-
VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice
-
Kamiyama M, Ichikawa Y, Ishikawa T, Chishima T, Hasegawa S, Hamaguchi Y et al. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther 2002; 9: 197-201.
-
(2002)
Cancer Gene Ther
, vol.9
, pp. 197-201
-
-
Kamiyama, M.1
Ichikawa, Y.2
Ishikawa, T.3
Chishima, T.4
Hasegawa, S.5
Hamaguchi, Y.6
-
17
-
-
33645838598
-
Phase I study of antisense oligonucleotide against vascular endothelial growth factor: Decrease in plasma vascular endothelial growth factor with potential clinical efficacy
-
Levine AM, Tulpule A, Quinn DI, Gorospe G III, Smith DL, Hornor L et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006; 24: 1712-1719.
-
(2006)
J Clin Oncol
, vol.24
, pp. 1712-1719
-
-
Levine, A.M.1
Tulpule, A.2
Quinn, D.I.3
Gorospe III, G.4
Smith, D.L.5
Hornor, L.6
-
18
-
-
7444261960
-
Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity
-
Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 2004; 4(Suppl 2): S81-S85.
-
(2004)
Clin Colorectal Cancer
, vol.4
, Issue.SUPPL. 2
-
-
Konner, J.1
Dupont, J.2
-
19
-
-
0031454617
-
Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
-
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
-
(1997)
Cell
, vol.88
, pp. 277-285
-
-
O'Reilly, M.S.1
Boehm, T.2
Shing, Y.3
Fukai, N.4
Vasios, G.5
Lane, W.S.6
-
20
-
-
0038574455
-
Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells
-
Dkhissi F, Lu H, Soria C, Opolon P, Griscelli F, Liu H et al. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 2003; 14: 997-1008.
-
(2003)
Hum Gene Ther
, vol.14
, pp. 997-1008
-
-
Dkhissi, F.1
Lu, H.2
Soria, C.3
Opolon, P.4
Griscelli, F.5
Liu, H.6
-
21
-
-
0032510801
-
Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
-
Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A 1998; 95: 5579-5583.
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, pp. 5579-5583
-
-
Claesson-Welsh, L.1
Welsh, M.2
Ito, N.3
Anand-Apte, B.4
Soker, S.5
Zetter, B.6
-
22
-
-
0033014037
-
Angiostatin binds ATP synthase on the surface of human endothelial cells
-
Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999; 96: 2811-2816.
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, pp. 2811-2816
-
-
Moser, T.L.1
Stack, M.S.2
Asplin, I.3
Enghild, J.J.4
Hojrup, P.5
Everitt, L.6
-
23
-
-
0035940429
-
Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor
-
Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001; 98: 12 485-12 490.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
-
-
Rodriguez-Manzaneque, J.C.1
Lane, T.F.2
Ortega, M.A.3
Hynes, R.O.4
Lawler, J.5
Iruela-Arispe, M.L.6
-
24
-
-
0010712792
-
Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
-
Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400.
-
(1998)
Cell
, vol.92
, pp. 391-400
-
-
Brooks, P.C.1
Silletti, S.2
von Schalscha, T.L.3
Friedlander, M.4
Cheresh, D.A.5
-
25
-
-
0032578703
-
IL-12 regulates VEGF and MMPs in a murine breast cancer model
-
Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 1998; 78: 361-365.
-
(1998)
Int J Cancer
, vol.78
, pp. 361-365
-
-
Dias, S.1
Boyd, R.2
Balkwill, F.3
-
26
-
-
0034194237
-
Anti-angiogenic cues from vascular basement membrane collagen
-
Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000; 60: 2520-2526.
-
(2000)
Cancer Res
, vol.60
, pp. 2520-2526
-
-
Colorado, P.C.1
Torre, A.2
Kamphaus, G.3
Maeshima, Y.4
Hopfer, H.5
Takahashi, K.6
-
27
-
-
0033979905
-
Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
-
Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000; 275: 1209-1215.
-
(2000)
J Biol Chem
, vol.275
, pp. 1209-1215
-
-
Kamphaus, G.D.1
Colorado, P.C.2
Panka, D.J.3
Hopfer, H.4
Ramchandran, R.5
Torre, A.6
-
28
-
-
0030500450
-
New perspectives in clinical oncology from angiogenesis research
-
Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A: 2534-2539.
-
(1996)
Eur J Cancer
, vol.32 A
, pp. 2534-2539
-
-
Folkman, J.1
-
29
-
-
0034307327
-
Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase
-
Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000; 60: 5410-5413.
-
(2000)
Cancer Res
, vol.60
, pp. 5410-5413
-
-
Kim, Y.M.1
Jang, J.W.2
Lee, O.H.3
Yeon, J.4
Choi, E.Y.5
Kim, K.W.6
-
30
-
-
34147174392
-
Endostatin: Current concepts about its biological role and mechanisms of action
-
Digtyar AV, Pozdnyakova NV, Feldman NB, Lutsenko SV, Severin SE. Endostatin: current concepts about its biological role and mechanisms of action. Biochemistry (Mosc) 2007; 72: 235-246.
-
(2007)
Biochemistry (Mosc)
, vol.72
, pp. 235-246
-
-
Digtyar, A.V.1
Pozdnyakova, N.V.2
Feldman, N.B.3
Lutsenko, S.V.4
Severin, S.E.5
-
31
-
-
0037969161
-
Endostatin action and intracellular signaling: Beta-catenin as a potential target?
-
Dixelius J, Cross MJ, Matsumoto T, Claesson-Welsh L. Endostatin action and intracellular signaling: beta-catenin as a potential target? Cancer Lett 2003; 196: 1-12.
-
(2003)
Cancer Lett
, vol.196
, pp. 1-12
-
-
Dixelius, J.1
Cross, M.J.2
Matsumoto, T.3
Claesson-Welsh, L.4
-
32
-
-
0141621070
-
Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity
-
Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J Biol Chem 2003; 278: 37 895-37 901.
-
(2003)
J Biol Chem
, vol.278
-
-
Wickstrom, S.A.1
Alitalo, K.2
Keski-Oja, J.3
-
33
-
-
0037008721
-
Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1
-
Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002; 277: 27 872-27 879.
-
(2002)
J Biol Chem
, vol.277
-
-
Kim, Y.M.1
Hwang, S.2
Kim, Y.M.3
Pyun, B.J.4
Kim, T.Y.5
Lee, S.T.6
-
34
-
-
33344472286
-
Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action
-
Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607.
-
(2006)
Exp Cell Res
, vol.312
, pp. 594-607
-
-
Folkman, J.1
-
35
-
-
0037372436
-
Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells
-
Wajih N, Sane DC. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood 2003; 101: 1857-1863.
-
(2003)
Blood
, vol.101
, pp. 1857-1863
-
-
Wajih, N.1
Sane, D.C.2
-
36
-
-
0037160991
-
Mortality associated with Down's syndrome in the USA from 1983 to 1997: A population-based study
-
Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002; 359: 1019-1025.
-
(2002)
Lancet
, vol.359
, pp. 1019-1025
-
-
Yang, Q.1
Rasmussen, S.A.2
Friedman, J.M.3
-
37
-
-
0035667067
-
High serum endostatin levels in Down syndrome: Implications for improved treatment and prevention of solid tumours
-
Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001; 9: 811-814.
-
(2001)
Eur J Hum Genet
, vol.9
, pp. 811-814
-
-
Zorick, T.S.1
Mustacchi, Z.2
Bando, S.Y.3
Zatz, M.4
Moreira-Filho, C.A.5
Olsen, B.6
-
38
-
-
0037155610
-
Cancer therapy. Setbacks for endostatin
-
Marshall E. Cancer therapy. Setbacks for endostatin. Science 2002; 295: 2198-2199.
-
(2002)
Science
, vol.295
, pp. 2198-2199
-
-
Marshall, E.1
-
39
-
-
28244462515
-
Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve
-
Celik I, Surucu O, Dietz C, Heymach JV, Force J, Hoschele I et al. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 2005; 65: 11 044-11 050.
-
(2005)
Cancer Res
, vol.65
-
-
Celik, I.1
Surucu, O.2
Dietz, C.3
Heymach, J.V.4
Force, J.5
Hoschele, I.6
-
40
-
-
34547106834
-
Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells
-
Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 2007; 361: 79-84.
-
(2007)
Biochem Biophys Res Commun
, vol.361
, pp. 79-84
-
-
Ling, Y.1
Yang, Y.2
Lu, N.3
You, Q.D.4
Wang, S.5
Gao, Y.6
-
41
-
-
0027383944
-
Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation
-
Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157: 351-358.
-
(1993)
J Cell Physiol
, vol.157
, pp. 351-358
-
-
Murphy, A.N.1
Unsworth, E.J.2
Stetler-Stevenson, W.G.3
-
42
-
-
0042197340
-
TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism
-
Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003; 114: 171-180.
-
(2003)
Cell
, vol.114
, pp. 171-180
-
-
Seo, D.W.1
Li, H.2
Guedez, L.3
Wingfield, P.T.4
Diaz, T.5
Salloum, R.6
-
43
-
-
0037393850
-
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2
-
Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9: 407-415.
-
(2003)
Nat Med
, vol.9
, pp. 407-415
-
-
Qi, J.H.1
Ebrahem, Q.2
Moore, N.3
Murphy, G.4
Claesson-Welsh, L.5
Bond, M.6
-
44
-
-
11444266441
-
Cancer anti-angiogenic therapy
-
Shimizu K, Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull 2004; 27: 599-605.
-
(2004)
Biol Pharm Bull
, vol.27
, pp. 599-605
-
-
Shimizu, K.1
Oku, N.2
-
45
-
-
0035468642
-
Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer
-
Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2: 544-551.
-
(2001)
Lancet Oncol
, vol.2
, pp. 544-551
-
-
Dannenberg, A.J.1
Altorki, N.K.2
Boyle, J.O.3
Dang, C.4
Howe, L.R.5
Weksler, B.B.6
-
46
-
-
2442718070
-
Experimental study of the inhibitory effect of indomethacin on the growth and angiogenesis of human colon cancer xenografts
-
Wang HM, Zhang GY. Experimental study of the inhibitory effect of indomethacin on the growth and angiogenesis of human colon cancer xenografts. Di Yi Jun Yi Da Xue Xue Bao 2004; 24: 184-187.
-
(2004)
Di Yi Jun Yi Da Xue Xue Bao
, vol.24
, pp. 184-187
-
-
Wang, H.M.1
Zhang, G.Y.2
-
47
-
-
16644371877
-
Indomethacin induces apoptosis through inhibition of survivin regulated by beta-catenin/TCF4 in human colorectal cancer cells.]
-
Zhu HX, Zhang G, Wang YH, Zhou CQ, Bai JF, Xu NZ. [Indomethacin induces apoptosis through inhibition of survivin regulated by beta-catenin/TCF4 in human colorectal cancer cells.] Ai Zheng 2004; 23: 737-741.
-
(2004)
Ai Zheng
, vol.23
, pp. 737-741
-
-
Zhu, H.X.1
Zhang, G.2
Wang, Y.H.3
Zhou, C.Q.4
Bai, J.F.5
Xu, N.Z.6
-
48
-
-
33646241064
-
Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling
-
Lee A, Frischer J, Serur A, Huang J, Bae JO, Kornfield ZN et al. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res 2006; 66: 4378-4384.
-
(2006)
Cancer Res
, vol.66
, pp. 4378-4384
-
-
Lee, A.1
Frischer, J.2
Serur, A.3
Huang, J.4
Bae, J.O.5
Kornfield, Z.N.6
-
49
-
-
0033870756
-
Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3
-
Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6: 3056-3061.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3056-3061
-
-
Gutheil, J.C.1
Campbell, T.N.2
Pierce, P.R.3
Watkins, J.D.4
Huse, W.D.5
Bodkin, D.J.6
-
50
-
-
0035266184
-
Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist
-
Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yarernko B, Nechuta T et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res 2001; 61: 2232-2238.
-
(2001)
Cancer Res
, vol.61
, pp. 2232-2238
-
-
Kumar, C.C.1
Malkowski, M.2
Yin, Z.3
Tanghetti, E.4
Yarernko, B.5
Nechuta, T.6
-
51
-
-
34248399095
-
Pharmacology of epidermal growth factor inhibitors
-
Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers 2007; 22(Suppl 4): S24-S39.
-
(2007)
Int J Biol Markers
, vol.22
, Issue.SUPPL. 4
-
-
Toffoli, G.1
De Mattia, E.2
Cecchin, E.3
Biason, P.4
Masier, S.5
Corona, G.6
-
52
-
-
0036570203
-
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase
-
Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-2560.
-
(2002)
Cancer Res
, vol.62
, pp. 2554-2560
-
-
Hirata, A.1
Ogawa, S.2
Kometani, T.3
Kuwano, T.4
Naito, S.5
Kuwano, M.6
-
53
-
-
33644876381
-
Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: The wave of the future in cancer therapy
-
Penne K, Bohlin C, Schneider S, Allen D. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs 2005; 28: 481-486.
-
(2005)
Cancer Nurs
, vol.28
, pp. 481-486
-
-
Penne, K.1
Bohlin, C.2
Schneider, S.3
Allen, D.4
-
54
-
-
0033561522
-
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
-
Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
-
(1999)
Cancer Res
, vol.59
, pp. 1935-1940
-
-
Huang, S.M.1
Bock, J.M.2
Harari, P.M.3
-
55
-
-
0033954292
-
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
-
Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18: 708-715.
-
(2000)
J Clin Oncol
, vol.18
, pp. 708-715
-
-
Fine, H.A.1
Figg, W.D.2
Jaeckle, K.3
Wen, P.Y.4
Kyritsis, A.P.5
Loeffler, J.S.6
-
56
-
-
0035957682
-
Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect
-
Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 2001; 495: 159-166.
-
(2001)
FEBS Lett
, vol.495
, pp. 159-166
-
-
Vincent, L.1
Chen, W.2
Hong, L.3
Mirshahi, F.4
Mishal, Z.5
Mirshahi-Khorassani, T.6
-
57
-
-
0028344887
-
Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470)
-
Yamamoto T, Sudo K, Fujita T. Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res 1994; 14: 1-3.
-
(1994)
Anticancer Res
, vol.14
, pp. 1-3
-
-
Yamamoto, T.1
Sudo, K.2
Fujita, T.3
-
58
-
-
20244381828
-
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin
-
Satchi-Fainaro R, Mamluk R, Wang L, Short SM, NagyJA, Feng D et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 2005; 7: 251-261.
-
(2005)
Cancer Cell
, vol.7
, pp. 251-261
-
-
Satchi-Fainaro, R.1
Mamluk, R.2
Wang, L.3
Short, S.M.4
Nagy, J.A.5
Feng, D.6
-
59
-
-
0034907881
-
The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor
-
Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7: 1073-1078.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1073-1078
-
-
Yoshiji, H.1
Kuriyama, S.2
Kawata, M.3
Yoshii, J.4
Ikenaka, Y.5
Noguchi, R.6
-
60
-
-
11144239579
-
2-Methoxyestradiol inhibits hypoxia-inducible factor 1 alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma
-
Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Van Waes C. 2-Methoxyestradiol inhibits hypoxia-inducible factor 1 alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 2004; 10: 8665-8673.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 8665-8673
-
-
Ricker, J.L.1
Chen, Z.2
Yang, X.P.3
Pribluda, V.S.4
Swartz, G.M.5
Van Waes, C.6
-
61
-
-
0037320432
-
2-Methoxyestradiol, a promising anticancer agent
-
Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003; 23: 165-172.
-
(2003)
Pharmacotherapy
, vol.23
, pp. 165-172
-
-
Lakhani, N.J.1
Sarkar, M.A.2
Venitz, J.3
Figg, W.D.4
-
62
-
-
0036692153
-
The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis
-
Boivin D, Gendron S, Beaulieu E, Gingras D, Beliveau R. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther 2002; 1: 795-802.
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 795-802
-
-
Boivin, D.1
Gendron, S.2
Beaulieu, E.3
Gingras, D.4
Beliveau, R.5
-
63
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
-
64
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
O'Dwyer, P.J.4
Mitchell, E.P.5
Alberts, S.R.6
-
65
-
-
27944458472
-
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer
-
Hurwitz H, Kabbinavar F. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology 2005; 69(Suppl 3): 17-24.
-
(2005)
Oncology
, vol.69
, Issue.SUPPL. 3
, pp. 17-24
-
-
Hurwitz, H.1
Kabbinavar, F.2
-
66
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
-
67
-
-
50249185913
-
-
Miller KD, Sledge GW, Burstein HJ. Angiogenesis inhibition in the treatment of breast cancer: a review of studies presented at the 2006 San Antonio breast cancer symposium. Clin Adv Hematol Oncol 2007; 5: 1-12.
-
Miller KD, Sledge GW, Burstein HJ. Angiogenesis inhibition in the treatment of breast cancer: a review of studies presented at the 2006 San Antonio breast cancer symposium. Clin Adv Hematol Oncol 2007; 5: 1-12.
-
-
-
-
69
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
Siebels, M.6
-
70
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, M.D.4
Bukowski, R.M.5
Rixe, O.6
-
71
-
-
50249099861
-
-
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25: (2007 ASCO Annual Meeting proceedings Part 1. 18S):LBA1.
-
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25: (2007 ASCO Annual Meeting proceedings Part 1. 18S):LBA1.
-
-
-
-
72
-
-
84995908124
-
Bevacizumab and Cetuximab for the treatment of Metastatic Colorectal Cancer
-
National Insitute for Health and Clinical Excellence, accessed 4 October 2007
-
National Insitute for Health and Clinical Excellence. Bevacizumab and Cetuximab for the treatment of Metastatic Colorectal Cancer. NICE Technology Appraisal Guidance 118, 2007; http://www.nice.org.uk/nicemedia/pdf/word/ TA118GuidanceWord.doc [accessed 4 October 2007].
-
(2007)
NICE Technology Appraisal Guidance
, vol.118
-
-
-
73
-
-
33748985366
-
Intravitreal injection of Bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy
-
Mason JO III, Nixon PA, White MF. Intravitreal injection of Bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Opthalmol 2006; 142: 685-688.
-
(2006)
Am J Opthalmol
, vol.142
, pp. 685-688
-
-
Mason III, J.O.1
Nixon, P.A.2
White, M.F.3
-
74
-
-
33745782355
-
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
-
Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW JR et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
-
(2006)
Retina
, vol.26
, pp. 495-511
-
-
Rich, R.M.1
Rosenfeld, P.J.2
Puliafito, C.A.3
Dubovy, S.R.4
Davis, J.L.5
Flynn6
HW, J.R.7
-
75
-
-
33947732977
-
Angiogenesis: An organizing principle for drug discovery?
-
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
-
(2007)
Nat Rev Drug Discov
, vol.6
, pp. 273-286
-
-
Folkman, J.1
-
76
-
-
0141988568
-
Fundamental concepts of the angiogenic process
-
Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003; 3: 643-651.
-
(2003)
Curr Mol Med
, vol.3
, pp. 643-651
-
-
Folkman, J.1
-
77
-
-
0036088478
-
Mechanisms of normal and tumor-derived angiogenesis
-
Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002; 282: C947-C970.
-
(2002)
Am J Physiol Cell Physiol
, vol.282
-
-
Papetti, M.1
Herman, I.M.2
-
78
-
-
0028865988
-
Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
-
Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995; 55: 6161-6165.
-
(1995)
Cancer Res
, vol.55
, pp. 6161-6165
-
-
Mukhopadhyay, D.1
Tsiokas, L.2
Sukhatme, V.P.3
-
79
-
-
0031825702
-
Hypoxia-inducible factor 1: From molecular biology to cardiopulmonary physiology
-
Semenza GL, Agani F, Iyer N, Jiang BH, Leung S, Wiener C et al. Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology. Chest 1998; 114: (Suppl): 40S-45S.
-
(1998)
Chest
, vol.114
, Issue.SUPPL.
-
-
Semenza, G.L.1
Agani, F.2
Iyer, N.3
Jiang, B.H.4
Leung, S.5
Wiener, C.6
-
80
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
81
-
-
0023157363
-
Angiogenic factors
-
Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-447.
-
(1987)
Science
, vol.235
, pp. 442-447
-
-
Folkman, J.1
Klagsbrun, M.2
-
82
-
-
33745171739
-
Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions
-
Ding S, Li C, Lin S, Yang Y, Liu D, Han Y et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol 2006; 37: 861-866.
-
(2006)
Hum Pathol
, vol.37
, pp. 861-866
-
-
Ding, S.1
Li, C.2
Lin, S.3
Yang, Y.4
Liu, D.5
Han, Y.6
-
83
-
-
33745102388
-
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
-
Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006; 94: 1823-1832.
-
(2006)
Br J Cancer
, vol.94
, pp. 1823-1832
-
-
Des Guetz, G.1
Uzzan, B.2
Nicolas, P.3
Cucherat, M.4
Morere, J.F.5
Benamouzig, R.6
-
84
-
-
27244431905
-
Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: Comparison with an anti-CD31 monoclonal antibody
-
Yao Y, Kubota T, Takeuchi H, Sato K. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 2005; 25: 201-206.
-
(2005)
Neuropathology
, vol.25
, pp. 201-206
-
-
Yao, Y.1
Kubota, T.2
Takeuchi, H.3
Sato, K.4
-
85
-
-
2342514123
-
Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis
-
Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004; 64: 2941-2955.
-
(2004)
Cancer Res
, vol.64
, pp. 2941-2955
-
-
Uzzan, B.1
Nicolas, P.2
Cucherat, M.3
Perret, G.Y.4
-
86
-
-
0034648765
-
Angiogenesis in cancer and other diseases
-
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
-
(2000)
Nature
, vol.407
, pp. 249-257
-
-
Carmeliet, P.1
Jain, R.K.2
-
87
-
-
33748923637
-
Dormant tumors awaken by a short-term angiogenic burst: The spike hypothesis
-
Indraccolo S, Favaro E, Amadori A. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle 2006; 5: 1751-1755.
-
(2006)
Cell Cycle
, vol.5
, pp. 1751-1755
-
-
Indraccolo, S.1
Favaro, E.2
Amadori, A.3
-
88
-
-
0034660890
-
Fractals and cancer
-
Baish JW, Jain RK. Fractals and cancer. Cancer Res 2000; 60: 3683-3688.
-
(2000)
Cancer Res
, vol.60
, pp. 3683-3688
-
-
Baish, J.W.1
Jain, R.K.2
-
89
-
-
0023788067
-
Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules
-
Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95-109.
-
(1988)
Am J Pathol
, vol.133
, pp. 95-109
-
-
Dvorak, H.F.1
Nagy, J.A.2
Dvorak, J.T.3
Dvorak, A.M.4
-
90
-
-
0034161989
-
Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
-
Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-1393.
-
(2000)
Cancer Res
, vol.60
, pp. 1388-1393
-
-
Eberhard, A.1
Kahlert, S.2
Goede, V.3
Hemmerlein, B.4
Plate, K.H.5
Augustin, H.G.6
-
91
-
-
0242624629
-
Molecular basis of angiogenesis and cancer
-
Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 2003; 22: 6549-6556.
-
(2003)
Oncogene
, vol.22
, pp. 6549-6556
-
-
Tonini, T.1
Rossi, F.2
Claudio, P.P.3
-
92
-
-
0028822834
-
Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
-
Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-4580.
-
(1995)
Cancer Res
, vol.55
, pp. 4575-4580
-
-
Rak, J.1
Mitsuhashi, Y.2
Bayko, L.3
Filmus, J.4
Shirasawa, S.5
Sasazuki, T.6
-
93
-
-
0033614962
-
Essential role for oncogenic Ras in tumour maintenance
-
Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400: 468-472.
-
(1999)
Nature
, vol.400
, pp. 468-472
-
-
Chin, L.1
Tam, A.2
Pomerantz, J.3
Wong, M.4
Holash, J.5
Bardeesy, N.6
-
94
-
-
0042972556
-
Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis
-
Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003; 3: 219-231.
-
(2003)
Cancer Cell
, vol.3
, pp. 219-231
-
-
Watnick, R.S.1
Cheng, Y.N.2
Rangarajan, A.3
Ince, T.A.4
Weinberg, R.A.5
-
95
-
-
22944447177
-
Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: Justification for K-ras-directed therapy
-
Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 2005; 3: 413-423.
-
(2005)
Mol Cancer Res
, vol.3
, pp. 413-423
-
-
Fleming, J.B.1
Shen, G.L.2
Holloway, S.E.3
Davis, M.4
Brekken, R.A.5
-
97
-
-
33645907503
-
Inflammation and cancer: The role of the immune response and angiogenesis
-
Dalgleish AG, O'Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res 2006; 130: 1-38.
-
(2006)
Cancer Treat Res
, vol.130
, pp. 1-38
-
-
Dalgleish, A.G.1
O'Byrne, K.2
-
98
-
-
0035902802
-
Chronic immune activation and inflammation as the cause of malignancy
-
O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001; 85: 473-483.
-
(2001)
Br J Cancer
, vol.85
, pp. 473-483
-
-
O'Byrne, K.J.1
Dalgleish, A.G.2
-
99
-
-
0027970092
-
Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
-
O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
-
(1994)
Cell
, vol.79
, pp. 315-328
-
-
O'Reilly, M.S.1
Holmgren, L.2
Shing, Y.3
Chen, C.4
Rosenthal, R.A.5
Moses, M.6
-
100
-
-
0029098530
-
Antibody-directed targeting of the vasculature of solid tumors
-
Thorpe PE, Burrows FJ. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995; 36: 237-251.
-
(1995)
Breast Cancer Res Treat
, vol.36
, pp. 237-251
-
-
Thorpe, P.E.1
Burrows, F.J.2
-
101
-
-
0033597130
-
Endostatin induces endothelial cell apoptosis
-
Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274: 11721-11726.
-
(1999)
J Biol Chem
, vol.274
, pp. 11721-11726
-
-
Dhanabal, M.1
Ramchandran, R.2
Waterman, M.J.3
Lu, H.4
Knebelmann, B.5
Segal, M.6
-
102
-
-
0036985699
-
Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications
-
Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29(Suppl 16): 10-14.
-
(2002)
Semin Oncol
, vol.29
, Issue.SUPPL. 16
, pp. 10-14
-
-
Ferrara, N.1
-
103
-
-
34447258681
-
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
-
Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101: 937-949.
-
(2007)
J Cell Biochem
, vol.101
, pp. 937-949
-
-
Fukumura, D.1
Jain, R.K.2
-
104
-
-
0023909330
-
Determinants of tumor blood flow: A review
-
Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48: 2641-2658.
-
(1988)
Cancer Res
, vol.48
, pp. 2641-2658
-
-
Jain, R.K.1
-
105
-
-
0017344325
-
Changes in blood viscosity and plasma proteins in carcinoma
-
Tietjen GW, Chien S, Scholz P, Gump FE, Kinney JM. Changes in blood viscosity and plasma proteins in carcinoma. J Surg Oncol 1977; 9: 53-59.
-
(1977)
J Surg Oncol
, vol.9
, pp. 53-59
-
-
Tietjen, G.W.1
Chien, S.2
Scholz, P.3
Gump, F.E.4
Kinney, J.M.5
-
106
-
-
0016437023
-
Effect of fibrinogen on aggregation of red cells and on apparent viscosity of artificial thrombi in haemophilia, myocardial infarction, thyroid disease, cancer and control systems: Effect of ABO blood groups
-
Dintenfass L, Forbes CD. Effect of fibrinogen on aggregation of red cells and on apparent viscosity of artificial thrombi in haemophilia, myocardial infarction, thyroid disease, cancer and control systems: effect of ABO blood groups. Microvasc Res 1975; 9: 107-118.
-
(1975)
Microvasc Res
, vol.9
, pp. 107-118
-
-
Dintenfass, L.1
Forbes, C.D.2
-
107
-
-
0028025011
-
Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows
-
Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994; 54: 4564-4568.
-
(1994)
Cancer Res
, vol.54
, pp. 4564-4568
-
-
Yuan, F.1
Salehi, H.A.2
Boucher, Y.3
Vasthare, U.S.4
Tuma, R.F.5
Jain, R.K.6
-
108
-
-
23444460271
-
Antiangiogenic therapy for cancer: Current and emerging concepts
-
Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 2005 19(Suppl 3):;7-16.
-
(2005)
Oncology (Williston Park)
, vol.19
, Issue.SUPPL. 3
, pp. 7-16
-
-
Jain, R.K.1
-
109
-
-
0035114055
-
The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer
-
Los M, Voest EE. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin Oncol 2001; 28: 93-105.
-
(2001)
Semin Oncol
, vol.28
, pp. 93-105
-
-
Los, M.1
Voest, E.E.2
-
110
-
-
0037189380
-
Tumor regression by targeted gene delivery to the neovasculature
-
Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296: 2404-2407.
-
(2002)
Science
, vol.296
, pp. 2404-2407
-
-
Hood, J.D.1
Bednarski, M.2
Frausto, R.3
Guccione, S.4
Reisfeld, R.A.5
Xiang, R.6
-
111
-
-
0037141466
-
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
-
Hori K, Saito S, Kubota K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 2002; 86: 1604-1614.
-
(2002)
Br J Cancer
, vol.86
, pp. 1604-1614
-
-
Hori, K.1
Saito, S.2
Kubota, K.3
-
112
-
-
2942593990
-
Anti-vascular tumor therapy: Recent advances, pitfalls and clinical perspectives
-
Eichhorn ME, Strieth S, Dellian M. Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist Updat 2004; 7: 125-138.
-
(2004)
Drug Resist Updat
, vol.7
, pp. 125-138
-
-
Eichhorn, M.E.1
Strieth, S.2
Dellian, M.3
-
113
-
-
0035908479
-
Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment
-
Fidler IJ. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 2001; 93: 1040-1041.
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 1040-1041
-
-
Fidler, I.J.1
-
114
-
-
0032719528
-
Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
-
Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726-2734.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2726-2734
-
-
Slaton, J.W.1
Perrotte, P.2
Inoue, K.3
Dinney, C.P.4
Fidler, I.J.5
-
115
-
-
0037251744
-
Resistance in the anti-angiogenic era: Nay-saying or a word of caution?
-
Sweeney CJ, Miller KD, Sledge GW JR. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 2003; 9: 24-29.
-
(2003)
Trends Mol Med
, vol.9
, pp. 24-29
-
-
Sweeney, C.J.1
Miller, K.D.2
Sledge, G.J.3
-
116
-
-
0034087691
-
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
-
Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-R24.
-
(2000)
J Clin Invest
, vol.105
-
-
Klement, G.1
Baruchel, S.2
Rak, J.3
Man, S.4
Clark, K.5
Hicklin, D.J.6
-
117
-
-
33846441659
-
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
-
Kamat AA, Kim TJ, Landen CN JR, Lu C, Han LY, Lin YG et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007; 67: 281-288.
-
(2007)
Cancer Res
, vol.67
, pp. 281-288
-
-
Kamat, A.A.1
Kim, T.J.2
Landen3
CN, J.R.4
Lu, C.5
Han, L.Y.6
Lin, Y.G.7
-
118
-
-
0033580889
-
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
-
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
-
(1999)
Science
, vol.284
, pp. 1994-1998
-
-
Holash, J.1
Maisonpierre, P.C.2
Compton, D.3
Boland, P.4
Alexander, C.R.5
Zagzag, D.6
-
119
-
-
0033529618
-
Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
-
Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
-
(1999)
Circ Res
, vol.85
, pp. 221-228
-
-
Asahara, T.1
Masuda, H.2
Takahashi, T.3
Kalka, C.4
Pastore, C.5
Silver, M.6
-
120
-
-
0032887340
-
Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
-
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-752.
-
(1999)
Am J Pathol
, vol.155
, pp. 739-752
-
-
Maniotis, A.J.1
Folberg, R.2
Hess, A.3
Seftor, E.A.4
Gardner, L.M.5
Pe'er, J.6
-
121
-
-
0034687663
-
Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
-
Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000; 97: 14608-14613.
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 14608-14613
-
-
Chang, Y.S.1
di Tomaso, E.2
McDonald, D.M.3
Jones, R.4
Jain, R.K.5
Munn, L.L.6
-
122
-
-
0023909511
-
No-touch isolation technique in colon cancer: A controlled prospective trial
-
Wiggers T, Jeekel J, Arends JW, Brinkhorst AP, Kluck HM, Luyk CI et al. No-touch isolation technique in colon cancer: a controlled prospective trial. Br J Surg 1988; 75: 409-415.
-
(1988)
Br J Surg
, vol.75
, pp. 409-415
-
-
Wiggers, T.1
Jeekel, J.2
Arends, J.W.3
Brinkhorst, A.P.4
Kluck, H.M.5
Luyk, C.I.6
-
123
-
-
27644588474
-
Pancreatectomy using the no-touch isolation technique followed by extensive intraoperative peritoneal lavage to prevent cancer cell dissemination: A pilot study
-
Hirota M, Shimada S, Yamamoto K, Tanaka E, Sugita H, Egami H et al. Pancreatectomy using the no-touch isolation technique followed by extensive intraoperative peritoneal lavage to prevent cancer cell dissemination: a pilot study. JOP 2005; 6: 143-151.
-
(2005)
JOP
, vol.6
, pp. 143-151
-
-
Hirota, M.1
Shimada, S.2
Yamamoto, K.3
Tanaka, E.4
Sugita, H.5
Egami, H.6
-
124
-
-
0035064192
-
Premenopausal status accelerates relapse in node positive breast cancer: Hypothesis links angiogenesis, screening controversy
-
Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat 2001; 65: 217-224.
-
(2001)
Breast Cancer Res Treat
, vol.65
, pp. 217-224
-
-
Retsky, M.1
Demicheli, R.2
Hrushesky, W.3
-
125
-
-
4344587881
-
Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients
-
Retsky M, Bonadonna G, Demicheli R, Folkman J, Hrushesky W, Valagussa P. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res 2004; 6: R372-R374.
-
(2004)
Breast Cancer Res
, vol.6
-
-
Retsky, M.1
Bonadonna, G.2
Demicheli, R.3
Folkman, J.4
Hrushesky, W.5
Valagussa, P.6
-
126
-
-
0036219390
-
Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses
-
te Velde EA, Voest EE, van Gorp JM, Verheem A, Hagendoorn J, Gebbink MF et al. Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. Ann Surg Oncol 2002; 9: 303-309.
-
(2002)
Ann Surg Oncol
, vol.9
, pp. 303-309
-
-
te Velde, E.A.1
Voest, E.E.2
van Gorp, J.M.3
Verheem, A.4
Hagendoorn, J.5
Gebbink, M.F.6
-
127
-
-
0037963801
-
Neoadjuvant antiangiogenic therapy with tamoxifen does not impair gastrointestinal anastomotic repair in the rat
-
McNamara DA, Walsh TN, Kay E, Bouchier-Hayes DJ. Neoadjuvant antiangiogenic therapy with tamoxifen does not impair gastrointestinal anastomotic repair in the rat. Colorectal Dis 2003; 5: 335-341.
-
(2003)
Colorectal Dis
, vol.5
, pp. 335-341
-
-
McNamara, D.A.1
Walsh, T.N.2
Kay, E.3
Bouchier-Hayes, D.J.4
-
129
-
-
34347331382
-
Resection of hepatocellular carcinoma: The effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients
-
Tralhao JG, Kayal S, Dagher I, Sanhueza M, Vons C, Franco D. Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients. Hepatogastroenterology 2007; 54: 1200-1206.
-
(2007)
Hepatogastroenterology
, vol.54
, pp. 1200-1206
-
-
Tralhao, J.G.1
Kayal, S.2
Dagher, I.3
Sanhueza, M.4
Vons, C.5
Franco, D.6
-
130
-
-
0031894878
-
Perioperative blood transfusions reduce long-term survival following surgery for colorectal cancer
-
Edna TH, Bjerkeset T. Perioperative blood transfusions reduce long-term survival following surgery for colorectal cancer. Dis Colon Rectum 1998; 41: 451-459.
-
(1998)
Dis Colon Rectum
, vol.41
, pp. 451-459
-
-
Edna, T.H.1
Bjerkeset, T.2
-
131
-
-
36749037201
-
S-nitrosohemoglobin deficiency: A mechanism for loss of physiological activity in banked blood
-
Reynolds JD, Ahearn GS, Angelo M, Zhang J, Cobb F, Stamler JS. S-nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci U S A 2007; 104: 17058-17062.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 17058-17062
-
-
Reynolds, J.D.1
Ahearn, G.S.2
Angelo, M.3
Zhang, J.4
Cobb, F.5
Stamler, J.S.6
-
132
-
-
34250025453
-
Sample preparation and bioinformatics in MALDI profiling of urinary proteins
-
Zerefos P, Prados J, Kossida S, Kalousis A, Vlahou A. Sample preparation and bioinformatics in MALDI profiling of urinary proteins. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 853: 20-30.
-
(2007)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.853
, pp. 20-30
-
-
Zerefos, P.1
Prados, J.2
Kossida, S.3
Kalousis, A.4
Vlahou, A.5
-
133
-
-
33847173683
-
Functional imaging of colorectal cancer angiogenesis
-
Goh V, Padhani AR, Rasheed S. Functional imaging of colorectal cancer angiogenesis. Lancet Oncol 2007; 8: 245-255.
-
(2007)
Lancet Oncol
, vol.8
, pp. 245-255
-
-
Goh, V.1
Padhani, A.R.2
Rasheed, S.3
-
134
-
-
11144354392
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
-
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
-
(2004)
Nat Med
, vol.10
, pp. 145-147
-
-
Willett, C.G.1
Boucher, Y.2
di Tomaso, E.3
Duda, D.G.4
Munn, L.L.5
Tong, R.T.6
-
135
-
-
0347615101
-
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies
-
Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-3964.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3955-3964
-
-
Morgan, B.1
Thomas, A.L.2
Drevs, J.3
Hennig, J.4
Buchert, M.5
Jivan, A.6
|